Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 293.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 3.00 (1.034%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 293.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Hutchmed sinks on US FDA drug rejection

Tue, 03rd May 2022 11:29

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Vast Resources PLC, up 50% at 0.51 pence, 12-month range 0.08p-10.00p. The Romania and Zimbabwe-focused miner says revenue more than doubled to USD2.3 million in the first quarter from USD970,465 in the fourth quarter. Reports increase in tons milled and in dry-metric-ton production at the Baita Plai polymetallic mine in Romania.

----------

Eneraqua Technologies PLC, up 10% at 280.00p, up 1.1% from November listing price of 277.00p. The energy and water efficiency services provider wins contract from the Indian state government of Uttarakhand to reduce carbon emissions and improve water efficiency. The northern state has a population of over 10 million people. Contract is worth GBP900,000 from the state's Department of Horticulture will see Eneraqua supply systems to 340 horticultural farms across the state.

----------

AIM - LOSERS

----------

Hutchmed (China) Ltd, down 15% at 208.00p, 12-month range 202.50p-656.00p. The US Food & Drug Administration has rejected the drugmaker's surufatinib for treatment of pancreatic neuroendocrine tumours. In a complete response letter, the FDA said the current data package, based on two positive phase three trials in China and one bridging study in the US, does not support an approval in the US "at this time". The FDA said a multi-regional clinical trial of surufatinib required for US approval. Surufatinib was approved in China for the treatment of pNETs and extra-pancreatic neuroendocrine tumours in June 2021 and December 2020, respectively.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
11 Nov 2019 11:08

Hutchison's Surufatinib Gets New Drug Application Approval In China

Hutchison's Surufatinib Gets New Drug Application Approval In China

Read more
10 Oct 2019 15:45

Hutchison China Meditech expands collaboration with Innovent

(Sharecast News) - Hutchison China Meditech on Thursday confirmed the expansion of its tumour treatment collaboration agreement with Innovent Biologics Inc..

Read more
10 Oct 2019 12:43

Hutchison China Expands Tumour Treatment Collaboration With Innovent

Hutchison China Expands Tumour Treatment Collaboration With Innovent

Read more
4 Oct 2019 15:21

Hutchison Chi-Med initiates latest study of HMPL-523

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated an international phase 1 and 1b study of 'HMPL-523' - its novel spleen tyrosine kinase inhibitor - in patients with relapsed or refractory lymphoma, it announced on Friday.

Read more
4 Oct 2019 10:26

WINNERS & LOSERS SUMMARY: Astra Rises On Fasenra Approval In US

WINNERS & LOSERS SUMMARY: Astra Rises On Fasenra Approval In US

Read more
4 Oct 2019 08:39

Hutchison China Doses First Patient In HMPL-523 Lymphoma Study

Hutchison China Doses First Patient In HMPL-523 Lymphoma Study

Read more
3 Sep 2019 13:25

Hutchison China Starts Trial For HMPL-689 On Lymphoma Treatment

(Alliance News) - Hutchison China MediTech Ltd said Tuesday it has started its phase 1/1b study of small molecule inhibitor HMPL-689 in patients with advanced relapsed or refractory in the firm at

Read more
23 Aug 2019 11:25

Hutchison China MediTech launches trial for autoimmune disorder treatment

(Sharecast News) - Hutchison China MediTech has launched a clinical trial of HMPL-523, a novel spleen tyrosine kinase inhibitor, in patients with immune thrombocytopenia, an autoimmune disorder that can lead to increased risk of bleeding.

Read more
23 Aug 2019 10:59

Hutchison China Meditech Starts HMPL-523 Trial In China

(Alliance News) - Hutchison China Meditech Ltd on Friday said it has begun a phase 1 study of HMPL-523 as a treatment for immune thrombocytopenia in China, dosing the first patient on Monday last

Read more
30 Jul 2019 11:43

Hutchison China Interim Loss Widens On Expenses; Alters 2019 Guidance

(Alliance News) - Hutchison China MediTech Ltd on Tuesday said its loss widened in the first half of the year due to expenses, while it has reduced guidance on expenses and cash flow.Shares

Read more
23 Jul 2019 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 24 July Tullow OilHalf Year ResultsPaypointQ1 Year ResultsLaw

Read more
3 Jul 2019 13:42

Prudential Holds 5% Hutchison China Meditech Stake After Deal

(Alliance News) - Hutchison China Meditech Ltd on Wednesday said Prudential PLC held a 5.1% stake in the China-focused drug company.Following a deal on Friday last week, Prudential held in

Read more
28 Jun 2019 16:38

Hutchison China Meditech Confirms Discounted Nasdaq Offer Pricing

(Alliance News) - China-focused drug developer and distributor Hutchison China Meditech PLC said Friday the pricing of a secondary offer of its Nasdaq-listed shares has been fixed at USD24.00 also

Read more
14 Jun 2019 14:40

Hutchison Chi-Med makes progress with surufatinib

(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee (IDMC) of the phase 3 pivotal study of 'surufatinib' in advanced neuroendocrine tumors - extra-pancreatic (SANET-ep) had completed a planned interim analysis.

Read more
29 May 2019 12:38

Hutchison China Meditech Shareholders Approve Subdivision Of Shares (ALLISS)

LONDON (Alliance News) - Hutchison China Meditech Ltd on Wednesday said its shareholders have approved a subdivision of shares at its extraordinary general meeting.The pharmaceutical that a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.